Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines

P. Kumar Rao; Christopher Barker; Daniel G. Coit; Richard W. Joseph; Miguel Materin; Ramesh Rengan; Jeffrey Sosman; John A. Thompson; Mark R. Albertini; Genevieve Boland; William E. Carson; Carlo Contreras; Gregory A. Daniels; Dominick DiMaio; Alison Durham; Ryan C. Fields; Martin D. Fleming; Anjela Galan; Brian Gastman; Kenneth Grossman; Valerie Guild; Douglas Johnson; Giorgos Karakousis; Julie R. Lange; Kim Margolin; Sameer Nath; Anthony J. Olszanski; Patrick A. Ott; Merrick I. Ross; April K. Salama; Joseph Skitzki; Susan M. Swetter; Evan Wuthrick; Nicole R. McMillian; Anita Engh

doi:10.6004/jnccn.2020.0006

Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines

P. Kumar Rao, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, John A. Thompson, Mark R. Albertini, Genevieve Boland, William E. Carson, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth GrossmanValerie Guild, Douglas Johnson, Giorgos Karakousis, Julie R. Lange, Kim Margolin, Sameer Nath, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Evan Wuthrick, Nicole R. McMillian, Anita Engh

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.

Original language	English
Pages (from-to)	121-131
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2020.0006
State	Published - 2020

Access to Document

10.6004/jnccn.2020.0006

Cite this

Kumar Rao, P., Barker, C., Coit, D. G., Joseph, R. W., Materin, M., Rengan, R., Sosman, J., Thompson, J. A., Albertini, M. R., Boland, G., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Durham, A., Fields, R. C., Fleming, M. D., Galan, A., Gastman, B., ... Engh, A. (2020). Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 18(2), 121-131. https://doi.org/10.6004/jnccn.2020.0006

@article{caec3f71b830498b82eceaf9f84c5936,

title = "Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.",

author = "{Kumar Rao}, P. and Christopher Barker and Coit, {Daniel G.} and Joseph, {Richard W.} and Miguel Materin and Ramesh Rengan and Jeffrey Sosman and Thompson, {John A.} and Albertini, {Mark R.} and Genevieve Boland and Carson, {William E.} and Carlo Contreras and Daniels, {Gregory A.} and Dominick DiMaio and Alison Durham and Fields, {Ryan C.} and Fleming, {Martin D.} and Anjela Galan and Brian Gastman and Kenneth Grossman and Valerie Guild and Douglas Johnson and Giorgos Karakousis and Lange, {Julie R.} and Kim Margolin and Sameer Nath and Olszanski, {Anthony J.} and Ott, {Patrick A.} and Ross, {Merrick I.} and Salama, {April K.} and Joseph Skitzki and Swetter, {Susan M.} and Evan Wuthrick and McMillian, {Nicole R.} and Anita Engh",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} 2020 Harborside Press. All rights reserved.",

year = "2020",

doi = "10.6004/jnccn.2020.0006",

language = "English",

volume = "18",

pages = "121--131",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "2",

}

Kumar Rao, P, Barker, C, Coit, DG, Joseph, RW, Materin, M, Rengan, R, Sosman, J, Thompson, JA, Albertini, MR, Boland, G, Carson, WE, Contreras, C, Daniels, GA, DiMaio, D, Durham, A, Fields, RC, Fleming, MD, Galan, A, Gastman, B, Grossman, K, Guild, V, Johnson, D, Karakousis, G, Lange, JR, Margolin, K, Nath, S, Olszanski, AJ, Ott, PA, Ross, MI, Salama, AK, Skitzki, J, Swetter, SM, Wuthrick, E, McMillian, NR & Engh, A 2020, 'Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 2, pp. 121-131. https://doi.org/10.6004/jnccn.2020.0006

TY - JOUR

T1 - Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines

AU - Kumar Rao, P.

AU - Barker, Christopher

AU - Coit, Daniel G.

AU - Joseph, Richard W.

AU - Materin, Miguel

AU - Rengan, Ramesh

AU - Sosman, Jeffrey

AU - Thompson, John A.

AU - Albertini, Mark R.

AU - Boland, Genevieve

AU - Carson, William E.

AU - Contreras, Carlo

AU - Daniels, Gregory A.

AU - DiMaio, Dominick

AU - Durham, Alison

AU - Fields, Ryan C.

AU - Fleming, Martin D.

AU - Galan, Anjela

AU - Gastman, Brian

AU - Grossman, Kenneth

AU - Guild, Valerie

AU - Johnson, Douglas

AU - Karakousis, Giorgos

AU - Lange, Julie R.

AU - Margolin, Kim

AU - Nath, Sameer

AU - Olszanski, Anthony J.

AU - Ott, Patrick A.

AU - Ross, Merrick I.

AU - Salama, April K.

AU - Skitzki, Joseph

AU - Swetter, Susan M.

AU - Wuthrick, Evan

AU - McMillian, Nicole R.

AU - Engh, Anita

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc. Publisher Copyright: © 2020 Harborside Press. All rights reserved.

PY - 2020

Y1 - 2020

N2 - The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.

AB - The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.

UR - http://www.scopus.com/inward/record.url?scp=85082319200&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0006

DO - 10.6004/jnccn.2020.0006

M3 - Article

C2 - 32023533

AN - SCOPUS:85082319200

SN - 1540-1405

VL - 18

SP - 121

EP - 131

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this